Market Update (NASDAQ:GILD): Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA

[Business Wire] – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the company’s refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or “boosting” agent that . . . → Read More: Market Update (NASDAQ:GILD): Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA Similar Articles: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug